Loading clinical trials...

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot | Clinical Trials | Clareo Health

COMPLETED

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice

NCT03521908•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

A study to compare the risk of a major bleeding in participants who received 2 different blood thinning medications following a blood clot

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•An acute-care inpatient encounter with a principal or secondarydiagnosis of VTE, or an ambulatory-care encounter with any diagnosis of VTE
•An outpatient pharmacy claim for apixaban or warfarin during the 30-day period following the index encounter
•Continuous and comprehensive medical/drug coverage for ≥6 months preceding the index encounter

Exclusion Criteria

•Evidence of a trial fibrillation/flutter or chemotherapy/radiation therapy for malignancy (other than non-melanoma skin cancer) during 6-month period preceding first receipt of index therapy
•Evidence of VTE(VTE event)during 6-month period preceding index encounter
•Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period preceding first receipt of index therapy

Locations (1)

Local Institution

Princeton, New Jersey, United States

Key Dates

Start Date

June 13, 2016

Primary Completion Date

June 4, 2018

Completion Date

November 23, 2018

Last Updated

February 28, 2022

Enrollment

35,756

ACTUAL participants

Conditions

Venous Thromboembolism (VTE)

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

NCT07015905

Venous Thromboembolism (VTE)

View study

RECRUITING

External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients

NCT07310693

Venous Thromboembolism (VTE)Occult Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Inclusion Criteria

Exclusion Criteria

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients

Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer

The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients